Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients
Pooled result · Organ support or deathResult — go to the resultAdjusted odds ratio 0.81 95% CI 0.67–0.97Authors' conclusion
Therapeutic-dose anticoagulation was associated with reduced odds of organ support or death and, in this context, serves as a case study of how evidence emerges and is acted upon under conditions of uncertainty.
Study context
- Population
- Noncritically ill patients hospitalized for COVID-19
- Participants
- 6,362 patients7 randomized controlled trials (RCTs)
- Comparison
- Therapeutic-dose vs nontherapeutic-dose anticoagulation
- Outcome
- Organ support or death
Methodological detailsexploratory counterfactual sequential individual participant data meta-analysis (IPDMA), mixed-effects logistic regression
- Exploratory counterfactual sequential IPDMA
- Mixed-effects logistic regression
Pooled result
As reported in the abstract
Adjusted odds ratio
0.81
95% CI 0.67–0.97
By group
Therapeutic-dosevs Nontherapeutic-dose
adjusted OR 0.81 (95% CI 0.67–0.97)
Further pooled results
Organ support or death, exploratory counterfactual sequential IPDMA · May 2021, ≈13 months after first patient enrollment
- Pooled treatment effect became statistically significant
- adjusted OR 0.73 (0.58-0.91) (95% CI; 6 RCTs, n = 3,944)
- Exploratory
Safety
- Major bleeding was rare
- 0.8% vs 0.5%
Original publication
Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients. J Am Coll Cardiol. Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →